To include your compound in the COVID-19 Resource Center, submit it here.

FDA guidance closes pediatric Orphan loophole

FDA issued draft guidance Tuesday that is intended to close a “loophole” in its implementation of the Orphan Drug Act that drug companies have used to avoid conducting pediatric studies. The

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE